Bicara Therapeutics announced that ficerafusp alfa combined with pembrolizumab showed an estimated 31% overall survival rate at three years in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC), roughly doubling survival compared to standard care. The Phase 1/1b study demonstrated deep, durable tumor responses driven by TGF-β inhibition, with a favorable safety profile. Bicara is advancing a Phase 3 trial and plans a new dosing study to support long-term treatment. These results highlight ficerafusp alfa's potential as a best-in-class therapy for this difficult-to-treat cancer.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Industrial Development Funding (IDF) and Oaktree have committed $1.7 billion to support Bloom Energy's fuel cell technology for building AI cloud infrastructure for Nebius. This project will provide dedicated behind-the-meter power to meet the high c...
